Immunotherapy approach to Alzheimer's studied in fly models

(Press-News.org) Developing treatments that slow, if not halt, the neuronal loss and cognitive decline of Alzheimer's disease (AD) has proven to be a challenge. Among the scientists who have taken on that challenge are researchers at the University of Florida's McKnight Brain Institute in Gainesville, using the fruit fly Drosophila melanogaster as a model.

The scientists are investigating passive immunotherapy, one of the most promising approaches to blocking the amyloid-β42 (Aβ42) peptide, the main component of the amyloid plaques that damage the brain cells of patients with AD.

Monoclonal antibodies, the cornerstone of immunotherapy, do not easily penetrate the tightly packed cells of the blood–brain barrier. As alternatives to full antibodies, the University of Florida scientists generated transgenic flies expressing two anti-Aβ single chain variable fragments (scFv), known as scFv9 and scFv42.2.

Drosophila flies genetically modified to express human Aβ42 also co-expressed either scFv9 or scFv42.2. Each treatment reduced the loss of photoreceptor neurons due to Aβ42 toxicity and improved the insects' eye morphology. In addition, the flies' mushroom bodies, the brain structures involved in olfactory learning and memory, were protected.

Administering both scFv9 and scFv42.2 to the flies produced a synergistic protective activity, which suggests that both scFvs can simultaneously target different Aβ42 epitopes, the scientists said. This is the first time that two antibodies targeting different regions of Aβ42 have shown synergistic activities, thanks to the experimental flexibility of Drosophila.

In addition to immunotherapy, the scientists investigated the protective effects of a laboratory engineered secreted Heat shock protein 70 (secHsp70) on flies whose brain cells were accumulating Aβ42 extracellularly. Hsp70 is a chaperone that prevents and reverts protein misfolding but is primarily located inside the cell. In flies treated with extracellular secHsp70, the eyes were perfectly organized, cell death was reduced, calyces in the mushroom bodies were preserved, and locomotor function was improved.

The researchers determined that secHsp70 interacted directly with Aβ42 without affecting Aβ42 accumulation and aggregation in the flies' brains. Thus, the protective activity of secHsp70 may be mediated by stable binding to toxic Aβ42 species. This study is a new approach to broadly target amyloids outside the cell and block their ability to attack the surrounding neurons, the scientists said.

INFORMATION:

Abstract:

"Exploiting Drosophila as a platform to develop anti-amyloid strategies." Pedro Fernandez-Funez1,2, Jonantan Sanchez-Garcia1, Swati Khare1, Alfonso Martin-Peña1, Diego Rincon-Limas1,2. 1) Dept Neurology, Univ Florida, Gainesville, FL; 2) McKnight Brain Institute, Genetics Institute, and Center for Translational Research on Neurodegenerative Disorders.

Link: http://abstracts.genetics-gsa.org/cgi-bin/dros14s/showdetail.pl?absno=14531635

ABOUT GSA:

Founded in 1931, the Genetics Society of America (GSA) is the professional scientific society for genetics researchers and educators. The Society's more than 5,000 members worldwide work to deepen our understanding of the living world by advancing the field of genetics, from the molecular to the population level. GSA promotes research and fosters communication through a number of GSA-­‐sponsored conferences including regular meetings that focus on particular model organisms. GSA publishes two peer-­‐reviewed, peer-­edited scholarly journals: GENETICS, which has published high quality original research across the breadth of the field since 1916, and G3: Genes|Genomes|Genetics, an open-­access journal launched in 2011 to disseminate high quality foundational research in genetics and genomics. The society also has a deep commitment to education and fostering the next generation of scholars in the field. For more information about GSA, please visit http://www.genetics-gsa.org. Also follow GSA on Facebook at facebook.com/GeneticsGSA and on Twitter@GeneticsGSA.